Connect
← Return to Nubeqa Monotherapy vs Dual Therapy with ADT
Discussion
Nubeqa Monotherapy vs Dual Therapy with ADT
Prostate Cancer | Last Active: 2 days ago | Replies (18)Comment receiving replies
@jeffmarc In the LIBERTAS trial, "intermittent" means stopping ADT and continuing with just Apalutamide unless/until PSA hits 10.0. That's for mCSPC, specifically.
Replies to "@jeffmarc In the LIBERTAS trial, "intermittent" means stopping ADT and continuing with just Apalutamide unless/until PSA..."
Connect
@northoftheborder
Then we look into the definition of intermittent, “ occurring at irregular intervals; not continuous or steady.”
The LIBERTAS Study “intermittent use of androgen-deprivation therapy (ADT) in participants with metastatic castrate-sensitive prostate cancer (mCSPC) who reached a prostate-specific antigen (PSA) level < 0.2 “
By intermittent they mean if the PSA goes above that they would start back up ADT. It’s not a permanent ending, though it could be for some people. The study specifically says it is studying intermittent versus continuous use of ADT.